Reply: Clinical and biological effects of mifepristone treatment for psychotic treatment [2]

Neuropsychopharmacology

Volumn 31, Issue 12, 2006, Pages 2795-2797

  Keller, Jennifer ^a   Schatzberg, Alan F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; GLUCOCORTICOID; MIFEPRISTONE; PLACEBO;

BIOLOGICAL ACTIVITY; DEPRESSIVE PSYCHOSIS; DISTRESS SYNDROME; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; FISHER EXACT TEST; HOSPITALIZATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LETTER; PATHOGENESIS; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOSIS; REMISSION; SCHIZOPHRENIA; YATES CONTINUITY CORRECTION;

EID: 33751112982     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301171     Document Type: Letter

References (20)

1. Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF (2001a). Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 21: 516-521.
2. Belanoff JK, Kalehzan M, Sund B, Fleming Ficek SK, Schatzberg AF (2001b). Cortisol activity and cognitive changes in psychotic major depression. Am J Psychiatry 158: 1612-1616.
3. Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C et al (2002). An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 52: 386-392.
4. Carroll BJ (2004a). Sertraline and the Cheshire cat in geriatric depression. Am J Psychiatry 161: 759 (author reply 759).
5. Carroll BJ (2004b). Untreated depression and hippocampal volume loss. Am J Psychiatry 161: 1309.
6. DeBattista C, Belanoff JK, Schatzberg AF (2003). C-1073 (mifepristone) vs placebo add on to usual treatment of psychotic major depression. Presented at the 42nd Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico.
7. DeBattista C, Belanoff J (2004). A double-blind, placebo controlled trial of C-1073 (Mifepristone) in the treatment of psychotic major depression. Presented at the 43rd Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Peurto Rico.
8. Faries D, Herrera J, Rayamajhi J, DeBrota D, Demitrack M, Potter WZ (2000). The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res 34: 3-10.
9. Flores B, Kenna H, Keller J, Solvason HB, Schatzberg AF (2006). Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 31: 628-636.
10. Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW et al (2001). Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry 58: 965.
11. Keller J, Flores B, Gomez RG, Solvason HB, Kenna H, Williams G et al (2006). Cortisol circadian rhythm alterations in psychotic major depression. Biol Psychiatry 60: 275-281.
12. NY Times Editorial Desk (2003). Disclosure at the Medical Journals, September 30.
13. Ohayon MM, Schatzberg AF (2002). Prevalence of depressive episodes with psychotic features in the general population. Am J Psychiatry 159: 1855-1861.
14. Prudic J, Olfson M, Marcus SC, Fuller RB, Sackeim HA (2004). Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry 55: 301-312.
15. Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Anderson SW, Van Camper LE et al (2004). A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 24: 365-373.
16. Rubin RT, Carroll BJ (2004). Mifepristone (RU486) in the treatment of psychotic depression: re-evaluation of published data. Neuropsychopharmacology 29(Suppl 1): S203-S204.
17. Schatzberg AF, Rothschild AJ, Langlais PJ, Bird ED, Cole JO (1985). A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res 19: 57-64.
18. Schneider LS, Nelson JC, Clary CM, Newhouse P, Rama KRR, Krishnan Shiovitz T et al (2004). Dr Schneider and colleagues reply. Am J Psychiatry 161: 759-761.
19. Simpson GM, El Sheshai A, Loza N, Kingsbury SJ, Fayek M, Fawzy W (2005). An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression. J Clin Psychiatry 66: 598-602.
20. Wiedemann K, Lauer C, Loycke A, Pollmacher T, Durst P, Macher JP et al (1992). Antiglucocorticoid treatment disrupts endocrine cycle and nocturnal sleep pattern. Eur Arch Psychiatry Clin Neurosci 241: 372-375.